Incyte has grown revenue 15% a year over three years and 15% a year over five, with earnings per share compounding at 70%. Revenue growth, 3-year annual rate: +15% (Biotechnology median +21%). Revenue growth, 5-year rate: +15%, growth has picked up over the last three years. Earnings per share, 3-year rate: +70%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

INCYIncyte

HealthcareUSD

$128.15

$78.2052 weeks$129.88

Is it growing?

Is INCY growing?

Incyte has grown revenue 15% a year over three years and 15% a year over five, with earnings per share compounding at 70%.

+15%

Revenue growth, 3-year annual rate · Biotechnology median +21% · steady growth, ahead of inflation · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +15%
Revenue growth, 5-year rate · +15% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +70%
Earnings per share, 3-year rate · revenue +15% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed